Théa laboratory pushes its pawns in the United States

This specialist in ophthalmology relies on innovation to distinguish itself from heavyweights.

Théa sets out to conquer the United States. The French laboratory, specializing in ophthalmology, plans to sell its first drugs in the country from next year. It will do so first via the Swiss company Similasan, in which it has taken a stake and will become the majority shareholder in 2022. The Clermont-Ferrand laboratory will also sell its own drugs, on prescription, from the following year. These are two products in clinical development for the treatment of glaucoma.

The first independent ophthalmology laboratory in Europe, Théa is no newcomer to the international market. It already generates 75% of its turnover there (603 million euros last year). But in the United States, the business challenge promises to be more severe. It’s not easy to find a place on the shelves of large drugstore chains (CVS, Boots, etc.).

At the helm since 2008, Jean-Frédéric Chibret has accelerated the internationalization of the company and reinforced the bet on innovation, with a new product

This article is for subscribers only. You have 68% left to discover.

To cultivate one’s freedom is to cultivate one’s curiosity.

Continue reading your article for € 1 the first month

Already subscribed? Log in

.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.